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The contrasting catalytic eﬃciency and cancer
cell antiproliferative activity of stereoselective
organoruthenium transfer hydrogenation
catalysts†
Ying Fu,‡§a Carlos Sanchez-Cano,‡a Rina Soni,‡a Isolda Romero-Canelon,a
Jessica M. Hearn,b Zhe Liu,¶a Martin Wills*a and Peter J. Sadler*a
The rapidly growing area of catalytic ruthenium chemistry has provided new complexes with potential as
organometallic anticancer agents with novel mechanisms of action. Here we report the anticancer activity
of four neutral organometallic RuII arene N-tosyl-1,2-diphenylethane-1,2-diamine (TsDPEN) tethered
transfer hydrogenation catalysts. The enantiomers (R,R)-[Ru(η6-C6H5(CH2)3-TsDPEN-N-Me)Cl] (8) and
(S,S)-[Ru(η6-C6H5(CH2)3-TsDPEN-N-Me)Cl] (8a) exhibited higher potency than cisplatin against A2780
human ovarian cancer cells. When the N-methyl was replaced by N–H, i.e. to give (R,R)-[Ru(η6-Ph(CH2)3-
TsDPEN-NH)Cl] (7) and (S,S)-[Ru(η6-Ph(CH2)3-TsDPEN-NH)Cl] (7a), respectively, anticancer activity
decreased >5-fold. Their antiproliferative activity appears to be linked to their ability to accumulate in
cells, and their mechanism of action might involve inhibition of tubulin polymerisation. This appears to be
the ﬁrst report of the potent anticancer activity of tethered RuII arene complexes, and the structure–
activity relationship suggests that the N-methyl substituents are important for potency. In the National
Cancer Institute 60-cancer-cell-line screen, complexes 8 and 8a exhibited higher activity than cisplatin
towards a broad range of cancer cell lines. Intriguingly, in contrast to their potent anticancer properties,
complexes 8/8a are poor catalysts for asymmetric transfer hydrogenation, whereas complexes 7/7a are
eﬀective asymmetric hydrogenation catalysts.
Introduction
Platinum-group metal complexes, including those of Ru,1,2
Rh,3,4 Pd,5,6 Ir,7–10 Os,11–13 and Pt,14–18 have shown potent anti-
cancer activity in vitro and in vivo. Among them, the anticancer
activity of organometallic half-sandwich RuII complexes has
been well studied recently.19–27 Although these RuII complexes
share a similar general half-sandwich structure,28–30 their
mechanisms of action vary,27,31–33 as illustrated by the follow-
ing examples. (1) Complex DW1 (Scheme 1, compound 1),
developed by Meggers et al., is a potent inhibitor of glycogen
synthase kinase (GSK-3β); and induces apoptosis of cancer
cells through a p53 dependent pathway.34 (2) [Ru(η6-biphenyl)
(ethylenediamine)]PF6 (Scheme 1, compound 2) is believed to
target DNA; the labile Ru–Cl bond can undergo hydrolysis to
form Ru–OH2 intracellularly, whereas this hydrolysis is sup-
pressed extracellularly.35 The hydrolysis step generates a reac-
tive site on the Ru centre which can bind to DNA bases (e.g.
guanine) and lead to DNA double-strand breaks and apoptosis.
(3) [Ru(η6-arene)Cl2(pta)] {PTA = 1,3,5-triaza-7-phosphatricyclo-
[3.3.1.1]decane} (Scheme 1, compound 3) exhibits promising
anti-metastatic eﬀects in vitro and in vivo.36,37 (4) Ruthenium
arene paullone complexes, e.g. (η6-p-cymene){9-bromo-6-
[(α-picolyl-κN)imino-κN]-7,12-dihydroindolo[3,2-d][1]benzazepine}
chlororuthenium(II) chloride (Scheme 1, compound 4) are
putative cyclin-dependent kinase (CDK) inhibitors, showing
potent anticancer activity in vitro.38 (5) [Ru(η6-arene)(TsEn)Cl]
(Scheme 1, compound 5) is able to target cancer cells by altering
the NADH/NAD+ ratio in cells.27 There is much current interest
in exploring alternative profiles of reactivity for ruthenium arene
complexes. Progress in optimising activity has centred on modi-
fying the arene,39,40 the monodentate ligand,41–43 or chelating
ligand;44–51 and multinuclear ruthenium arene complexes can
also exhibit potent anticancer activity.52–54
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Organometallic half-sandwich RuII complexes have also
been shown to be outstanding catalysts for asymmetric trans-
fer hydrogenation of ketones and imines. Noyori and co-
workers55,56 first reported the synthesis and use of compound
N-[(1R,2R)-1,2-diphenylethyl]-4-methylbenzenesulfonamide
(p-cymene)ruthenium chloride 6 (Scheme 2) as a catalyst for
the asymmetric hydrogenation of ketones and imines giving
products in high enantiomeric excesses, using a number of
reducing agents including hydrogen gas, isopropanol/base,
and formic acid/triethylamine (FA/TEA).57,58 Some RuII arene
complexes are active both as hydrogenation catalysts and as
anticancer agents.27,59,60
There are four major connections between reported organo-
metallic half-sandwich RuII complexes in the apparently dis-
tinct fields of anticancer activity and catalysis. (i) Structural
similarity: they have the general structure [Ru(η6-arene)(YZ)
(X)], where YZ is typically a chelating diamine ligand (e.g. ethy-
lenediamine, N-tosylethylenediamine)61 and X is a halide (e.g.
Cl);62 (ii) the monodentate ligand, which has a similar func-
tion in both cases, is normally a leaving group for hydride for-
mation or coordination of biomolecules to the RuII centre, for
the catalytic and anticancer eﬀects, respectively;63–65 (iii) the
chelating ligand, which often plays an important role in the
selectivity of anticancer targets1 and regioselectivity in
catalysis;66–68 (iv) chirality, which is important for both of the
two families of complexes, plays a vital role in substrate and
target recognition.69–71
‘Tethered’ complexes such {N-[(1R,2R)-1,2-diphenylethyl-2-(3-
phenylpropylamino)]-4-methylbenzenesulfonamide}ruthenium
chloride (Scheme 2, compound 7) are known to be particularly
eﬀective catalysts, capable of performing the enantioselective
reduction of ketones and imines through an asymmetric
transfer hydrogenation (ATH) mechanism, illustrated in
Scheme 3.77 Further experiments using compounds carrying
TsDPEN derivatives with one alkyl substituent on the basic
nitrogens (Scheme 2, compound 8) have revealed the impor-
tance of the N–H bond for ketone reduction.72 This is presum-
ably due to lack of the –NH⋯OC interaction required for the
postulated six membered cyclic transition state of the ketone
reduction process (Scheme 3a).73 The hydrides illustrated in
Scheme 3 are known to be formed under the reaction con-
ditions.63,74,75 In contrast, compounds 8/8a are still eﬀective
Scheme 1 Examples of organometallic half-sandwich RuII complexes which exhibit anticancer activity. 1. DW1 (the R enantiomer of the DW 1/2
racemic mixture); 2. [Ru(η6-biphenyl)(ethylenediamine)]PF6; 3. [Ru(η6-p-cymene)Cl2(pta)] (PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane);
4. (η6-p-cymene){9-bromo-6-[(α-picolyl-κN)imino-κN]-7,12-dihydroindolo[3,2-d][1]benzazepine}chlororuthenium(II) chloride; 5. [Ru(η6-p-cymene)
(TsEn)Cl] (TsEn = p-methybenzene).
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for imine reduction under similar conditions as predicted, but
with lower reactivity when compared with catalysts 7/7a. As a
result of these observations, coupled with studies reported by
others,76,77 imine reduction is speculated to take place via the
transition state illustrated in Scheme 3b. In this ‘open’ tran-
sition state, no N–H⋯NvC bond is present, hence the N-alkyl-
ated catalysts 8 remain active.78 However, increased steric
hindrance imposed by the larger methyl group (replacing the
H atom) serve to lower their activity. Interestingly, the use of
complexes 6 and 7 showing the same chiral configuration at
the ligand for the reduction of ketones and imines results in
formation of products of opposite configuration.
In recent years, the fast growing field of catalysis using
ruthenium complexes has generated exciting new leads for
anticancer research, e.g. the Hoveyda–Grubbs catalyst was
demonstrated by Ott et al. to exhibit anticancer activity in
MCF-7 breast and HT29 colon cancer cell lines.79 We also have
recently reported a series of ruthenium complexes structurally
similar to Noyori catalyst 6 that show anticancer properties in
A2780 ovarian carcinoma cells. They reduce NAD+ to NADH
catalytically using formate as an hydride source,60 and their
antiproliferative activity is markedly increased when cells
are co-incubated with the complex and formate (Scheme 1,
compound 5).27
The only previous investigation of the anticancer activity of
tethered complexes used the amine-tethered RuIIarene [η6:η1-
C6H5(CH2)nNH2)RuCl2] (n = 2 or 3). These complexes could
form monofunctional adducts on DNA, but did not possess
high anticancer activity in vitro. Here we explore the anticancer
properties of catalytically active complexes 7/7a and 8/8a. The
tethered arene structure found in complexes 7 and 8 restricts
the movement of the N,N-chelated ligand TsDPEN within the
coordination sphere of the stereogenic ruthenium centre. This
greatly increases the conformational stability of the complexes
and hence comparisons of the anticancer activity of the
enantiomers may aid understanding of the role of chirality,
if any, in the mode of action of this class of complexes.
Results
Complexes 7 and 8 (Scheme 2) are enantiomerically-pure and
show diﬀerent catalytic eﬃciency. Each of the four complexes
illustrated in Scheme 2 exists predominantly in the diastereo-
isomeric form shown. To assign the chirality at each ruthe-
nium centre, Cahn–Ingold–Prelog priority rules (CIP system)
were used to define the priority sequence of ligands attached
Scheme 2 Half-sandwich RuII complexes containing a TsDPEN ligand; complexes 7/7a and 8/8a were studied in this work.
Scheme 3 (A) Mechanism of hydrogen transfer from the hydride
derived from 7 to a ketone, in which the hydrogen bond from the N–H
is required for ketone reduction. Complex 8, lacking this N–H bond, are
inactive in ketone reduction. (B) Mechanism of hydrogen transfer from
the hydride derived from 7 or 8 to an imine. The ‘open’ nature of the
transition state, without an intramolecular hydrogen bond, allows both
complexes to be eﬀective in the reduction of imines. Complex 8 is,
however, less active than 7 due to the additional steric hindrance
imposed by the methyl group compared to a proton.
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to the RuII centre: η6-C6 > Cl > CHN-Ts > CHNH. According to
the sequence rule of the R/S system, the configurations of the
RuII centre in these four chiral ruthenium arene complexes
are: 7 = SRu, 7a = RRu, 8 = RRu, 8a = SRu. The chirality details for
the two pairs of ruthenium diastereoisomers are: (SRu, RC, RC)-
7, (RRu, SC, SC)-7a, (RRu, RC, RC)-8 and (SRu, SC, SC)-8a
(Table 1A).
Antiproliferative activity
The potential to inhibit the growth of cultured cancer cells pro-
vides a useful initial screening of anticancer activity. Table 1A
shows the ability of complexes 7 and 8 to inhibit the prolifer-
ation of A2780 human ovarian carcinoma cells (GI50 values in
µM). It is notable that the most eﬃcient catalysts show the
least anticancer activity. Complexes 7 and 7a were 5–10 fold
less active than 8 and 8a, which were more active than cispla-
tin. Complexes containing the RR isomers of the TsDPEN-
based chelated ligand showed better activity than complexes
with the SS isomer.
The four RuII complexes were further tested in the NCI-60
panel.96,97 Their potency was comparable to that measured in
A2780 cells (Tables 1B and S1†). Enantiomers 8 and 8a showed
similar potency with the same mean GI50 value of 1.62 μM.
This activity was similar to that of cisplatin (mean GI50 value =
1.49 μM). However, 7 and 7a were much less active than 8, 8a
and cisplatin with mean GI50 values >10 μM.
GI50 mean graphs
Selectivity in the NCI-60 screen can be displayed in mean
graphs, which plot positive and negative bars for each cell line
relative to a central line which represents the mean GI50
(Fig. 1). Negative values projecting to the right represent
higher cellular sensitivities for 8 or 8a compared with the
mean value, whereas positive values projecting to the left
represent lower cell line sensitivities for 8 or 8a compared to
the average. It can be seen in Fig. 1 that the selectivities of 8
and 8a for the diﬀerent cell lines are similar.
Complex 8 showed a broad spectrum of activity, with GI50
values ranging from 0.13 to 11.7 µM, with the highest activity
in CCRF-CEM (leukemia), K-562 (leukemia), NCI-H522
Fig. 1 Overlay of mean graphs for antiproliferative activity (GI50 values)
of ruthenium complexes 8 and 8a in the NCI-60 cell line screen. The
positive and negative values are plotted along a vertical line that rep-
resents the mean response of all the cell lines in the panel to 8 and 8a.
Bars to the right (log scale) indicate activity higher than the mean.
Table 1 (A) Chiral and biological properties of complexes 7/7a and
8/8a. (B) MG-MID (mean-graph midpoint) values for anticancer activity
of 8 and 8a against the human tumour 60-cell line panel: GI50 (the con-
centration which inhibits cell growth by 50%): TGI (the concentration
which inhibits cell growth by 100%); LC50 (the concentration which kills
50% of the original cells)
(A)
Complex
Chirality
GI50/µM
(A2780)
IC50/µM (MT polymeris-
ation inhibition)Ligand Metal
7 R,R S 5.5 ± 0.5 1.1 ± 0.1
7a S,S R 13.7 ± 0.4 1.5 ± 0.2
8 R,R R 1.2 ± 0.3 17 ± 3
8a S,S S 1.8 ± 0.2 25 ± 3
Cisplatin 2.0 ± 0.2
Colchicine 1.4a
Vinblastine 0.13a
(B)
Complexb GI50 (µM) TGI (µM) LC50 (µM)
7 >10c NA NA
7a >10c NA NA
8 1.62 4.16 14.45
8a 1.62 4.07 18.62
Cisplatin 1.49 9.33 44.0
a Colchicine and vinblastine IC50 values reported previously.
93
b Complexes 7 and 7a did not show significant antiproliferative activity
(i.e. GI50 > 10 µM) in the 60 cell lines tested by the NCI. Cisplatin data
from NCI/DTP screening: March 2012, 48 h incubation. c The
maximum concentration tested by the NCI.
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(non-small cell lung), SW-620 (colon), DU-145 (prostate) and
MDA-MB-168 (breast) cell lines, with GI50 values in the nM–μM
range. The total growth inhibition (TGI) values ranged from
1.3 to 33.9 µM; and 50% lethal concentration (LC50) values
ranging from 3.7 to >100 µM. Complex 8a also showed a broad
spectrum of activity, with GI50 values ranging from 0.26
to 8.3 µM, with the highest anticancer activity in K-562
(leukemia), NCI-H522 (non-small cell lung), HCT-116 (colon),
U251 (central nervous system) and MDA-MB-168 (breast) cell
lines, again with GI50 values in the nM–μM range. The TGI and
LC50 values ranged from 1.6 to 21.6 µM and 4.8 µM to
>100 µM, respectively. In comparison, the renal cell lines in
general showed low sensitivity to both 8 and 8a. This is
a common observation in screening as these cell lines are
chemoresistant, likely owing to their high levels of multi-drug
resistant proteins.80
COMPARE analysis
The patterns of sensitivity in the GI50, TGI and LC50 mean
graphs for 8 and 8a, were compared to the patterns of sensi-
tivity for compounds populating the NCI/NIH databases using
the COMPARE algorithm.97 The top 10 positive correlations in
both the Standard Agents and Synthetic Agents database were
considered, with Pearson correlation coeﬃcients (r) > 0.6.
Tables S2 and S3† show the results of this analysis. The corre-
lations are to an agent (mercaptoacetate) that can interact with
(and in some cases cleave) DNA, to two agents that can interact
with RNA machinery (rifamycin SV and caracemide), to one
anti-angiogenic compound (withaferin A), and an agent which
inhibits flavoproteinthioredoxin reductase (pleurotin). All
other positive correlations were <0.6 and therefore not deemed
significant. This analysis indicates that there are very few sig-
nificant correlations with either database and therefore pro-
vides little insight into the mechanism of action (MoA).
However, it does suggest that catalysts 8 and 8a have novel
MoAs compared to the other compounds populating the NCI/
NIH database.
We assessed quantitatively the similarity in mean graphs of
8 and 8a (Table S4†), giving correlation values at 0.868 (GI50
mean graph), 0.945 (TGI mean graph) and 0.942 (LC50 mean
graph). These highly significant correlations confirm the
observations in Fig. 1 and suggest that the mirror-image com-
plexes 8 and 8a have the same MoA. The lack of correlation of
activity for either of these compounds to the square-planar PtII
drug cisplatin confirms that even though they have similar
potencies, their MoA is diﬀerent, and is reflected in the A2780
and NCI-60 screening.
Interactions with nucleobases and aqueous stability
Since DNA is a potential target for transition metal anticancer
drugs,81,82 reactions of complex 8a with nucleobases 9-ethyl-
guanine (9-EtG) and 9-methyladenine (9-MeA) were investi-
gated by 1H NMR spectroscopy. No reaction between these
nucleobases and the Ru complex was observed after 24 h at
310 K (Fig. S1 and S2†). The NMR data showed that these
DNA bases bind very weakly, and that the arene and N,N′-
chelated ligands are strongly bound in aqueous solution. Sub-
stitution of the monodentate ligand would be expected to be
facile since the 16-electron catalyst is known to be readily
formed.78
Interactions with coenzyme NADH
In recent years, a number of half-sandwich RuII, OsII arene and
IrIII cyclopentadienyl anticancer complexes have been shown
to oxidise reduced coenzyme NADH to NAD+ with formation of
corresponding metal hydride complexes.27,83,84 Consequently,
reactions of complex 8a with NADH were investigated.
However, no reaction between NADH and the complex was
observed after 3 h at 298 K (Fig. S3†). In contrast, formation of
a ruthenium hydride derived from 8 can be observed when the
complex is treated with formic acid.78
However, the antiproliferative activity of complexes 7/8 was
increased by 5–25% upon co-incubation with sodium formate
(Fig. S4†). This improvement is quite dramatic for complexes 7
and 7a (25% reduced cell proliferation when co-incubated
with 2 mM formate), but less significant for the less-eﬃcient
catalysts; 8 and 8a (5%).
Cell cycle arrest
Since complexes 7/8 did not interact with the cellular targets
previously observed for related ruthenium complexes, we
analysed their eﬀect over the cell cycle of A2780 cancer cells by
propidium iodide staining and flow cytometry. Treatment with
2 µM 7/8 led to diﬀerent eﬀects; 7 and 7a induced S and G2/M
arrest, while 8 and 8a arrested the cell cycle of A2780 in G2/M
(Fig. 2).
Cellular accumulation
Cellular uptake plays an important role in antiproliferative
activity.85 A2780 cells were treated for 24 h with diﬀerent
Fig. 2 Changes in the cell cycle of A2780 human ovarian carcinoma
cells after 24 h treatment with 2 µM of complexes 7, 7a, 8 and 8a.
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concentrations (2 µM or GI50 concentration) of complexes 7/8,
and the cell accumulation of Ru was measured using ICP-MS.
Fig. 3 shows that 8 and 8a were accumulated to a much greater
extent compared to 7 and 7a when cells were incubated with
the same concentration of the complexes (2 µM, Fig. 3A). Fur-
thermore, A2780 cells accumulated similar amounts of Ru
when treated with concentrations of the complexes that
induced the same cell growth inhibition (GI50 concentrations,
Fig. 3B).
When the compartmentalisation of Ru within the cells was
determined, we found that most of the Ru was in the cytosol,
with less Ru located in the membranes (although significantly
high amounts for 8 and 8a) and in the cytoskeleton, and little
in the nucleus (Fig. 4 and S5†). This finding also supports the
conclusion that the complexes in this family do not target
nuclear DNA, in contrast to e.g. ethylenediamine ruthenium
arene anticancer complexes.41,42 Similar amounts of Ru from 8
and 8a were found in the various fractions when A2780 cells
were treated with GI50 (1.2 and 1.8 µM, respectively) or 2 µM
concentrations (Fig. 4B), but significantly increased amounts
of Ru from 7 and 7a when cells were treated with GI50 concen-
trations of 7 and 7a, which are 2.8× and 6.9×, respectively,
higher than 2 µM (Fig. 4A).
Microtubule polymerisation inhibition
The data for cellular distribution show that cells treated with
complexes 7/8 accumulate up to 25% of the drug in the cyto-
skeletal fraction (Fig. 4, S5 and S6†). This unusual pattern
strongly indicates that complexes 7/8 may target cytoskeletal
proteins including tubulin (protein component of micro-
tubules), actin (component of microfilaments) and lamin (com-
ponent of intermediate filaments). It is known that G2/M arrest
can be induced by tubulin-targeting molecules; our flow cytome-
try analysis confirmed this suggestion (Fig. S7†).86,87 To test this
hypothesis, we investigated the ability of complexes 7/8 to
aﬀect tubulin polymerisation using a fluorescence-based assay.
Fig. 5 and Table 1 show that 7/8 inhibit tubulin polymerisation
with potency following the trend 7 > 7a > 8 > 8a. The IC50
values (concentrations which cause 50% polymerisation inhi-
bition) vary from 1.1 to 15.3 µM which is at the same order of
magnitude as the GI50 values against cancer cell lines. More
importantly, a correlation between the ability of the complexes
to inhibit microtubule polymerisation, and the amount of
Fig. 3 Accumulation of Ru in A2780 human ovarian carcinoma cells
(expressed as ng Ru/106 cells) after 24 h treatment with (A) 2 µM and
(B) GI50 concentrations of 7/7a or 8/8a.
Fig. 4 Ru content of the cellular fractions of A2780 ovarian carcinoma
cells (expressed in ng Ru/106 cells) after 24 h treatment with (A) 2 µM
and (B) GI50 concentrations of 7/8.
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complex found in the cytoskeleton of treated cells (at GI50 con-
centration) is observed (Fig. 6).
Discussion
Our experiments show that 7–8 inhibit the proliferation of
A2780 ovarian carcinoma cells with diﬀerent eﬃciency. The
N-methyl complexes 8 (RRu, RC, RC) and 8a (SRu, SC, SC) are
more active than cisplatin, whereas the N–H complexes 7
(SRu, RC, RC) and 7a (RRu, SC, SC) are less potent. The trend in
the antiproliferative properties (8, 8a > 7 > 7a) is the inverse of
that for catalytic activity. Remarkably, subtle structural diﬀer-
ences between the four complexes result in dramatic diﬀer-
ences in their anticancer activity.
(i) The GI50 values in A2780 ovarian carcinoma cells
of [Ru(η6-benzene-(CH2)3-TsDPEN-N-X)Cl] complexes (7/8)
increase up to an order of magnitude (5–13 µM for 7/7a com-
pared to 1–2 µM for 8/8a) when the N–H group located at the
basic nitrogen atom in the (η6-benzene-(CH2)3-TsDPEN-N-X)
chelating ligand (7/7a) is replaced by an N-methyl group (8/8a).
A similar trend was also observed for the NCI-60 cell line
panel; the mean GI50 values for 7 and 7a were >10 µM. This
observation suggests that an NH group on the chelated ligand
is not essential for antiproliferative activity, unlike the
ethylenediamine series [Ru(η6-arene)(ethylenediamine)Cl]PF6
where it appears to play a role in H-bonding to the C6O of
guanine when bound to DNA via N7.88
(ii) Although COMPARE analysis suggests that enantiomers
probably have a similar mode of action, complexes containing
RR-ligands (7 and 8) show higher activity than SS-isomers
(7a and 8a), suggesting that ligand chirality influences their
biological activity. Such eﬀects might arise for example if
(chiral) proteins are the targets. Additionally, the NCI-60 panel
screening for 8 and 8a show that both enantiomers possess a
diﬀerential selectivity towards individual cell lines (although
they showed the same mean GI50 value).
This antiproliferative activity for 7–8 is not the result of the
interaction of the complexes with NADH or nucleotides (as
observed for structurally-related complexes).27,41,42 Perhaps it
is not surprising that Ru centres which can form relatively
stable 16-electron complexes (pseudo-5-coordinate) bind rela-
tively weakly to 6th ligands such as DNA bases. Nevertheless, a
decrease in the proliferation of A2780 cells was observed when
7 and 8 were co-incubated with a hydride source (sodium
formate);60 suggesting that these compounds might be able to
perform catalytic reactions inside cells. This increase in
activity follows the trend previously observed for the catalytic
properties of the complexes (7 ≫ 8), and is significant for 7
and 7a (25% decrease in cell growth), making these complexes
promising hydrogen-activated prodrugs. However, 8 and 8a are
still more eﬃcient in inhibiting the proliferation of A2780
cells, even in presence of sodium formate.
The diﬀerence in activity of 7 and 8 can be partially
explained by diﬀerences in the cellular accumulation of the
complexes. More Ru is found in A2780 ovarian carcinoma cells
treated with 2 µM of the more active 8 or 8a than in cells
treated with the same concentration of the less active 7 or 7a.
Additionally, similar quantities of Ru were found in
A2780 cells treated with GI50 concentrations of 7/7a or 8/8a.
The less eﬃcient accumulation (perhaps uptake) of 7 and 7a
by cells might be a key factor in lowering their antiproliferative
activity.
The cellular targets for 7/8 are most likely to be found in
the cytosol of treated cells, where the drugs mainly accumu-
late. However, up to 25% of the Ru taken up by cells is found
Fig. 5 IC50 values (µM) for inhibition of microtubule polymerization
inhibition (MTI) in vitro by complexes 7/8 compared to colchicine and
vinblastine (values taken from ref. 93).
Fig. 6 Plot showing the correlation between the ability of complexes
7–8 to inhibit the microtubule polymerisation in vitro (expressed as
IC50/µM), and the amount of Ru found in the cytoskeleton of A2780
cells treated with GI50 concentrations of the complexes (expressed as ng
Ru/106 cells).
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in the cytoskeleton (Fig. 4, S5 and S6†). Based on the cellular
distribution data and G2/M phase cell cycle arrest observed,
we hypothesised that targets could also be located in the cyto-
skeleton of the treated cells.
Microtubules are cycloskeletal polymers that show dynamic
behaviour, polymerising and depolymerising multiple times
upon hydrolysis of GTP.89 They form a scaﬀold that is in con-
stant reorganisation, and yet serves as a stable source of
polarity information across the cell, separating the replicated
chromosomes between the two daughter cells during cell
division through the formation of the mitotic spindle.90 This
makes them important targets for the treatment of cancer, as
disruption of the dynamic nature of microtubules stops cell
proliferation and leads to apoptosis. Drugs such as taxanes
(e.g. taxol) which stabilise microtubules and vinca alkaloids
(e.g. vinblastine) which inhibit the formation of microtubules,
are already used clinically as anticancer chemotherapeutic
agents.91 The TsDPEN ligand in complexes 7/8 shows structural
similarities with the active conformation of a new series of light
activated compounds capable of inhibiting the formation of
microtubules by mimicking colchicine.92 Complexes 7 and 7a
inhibit the polymerisation of microtubules in vitro (IC50 of
1.1 µM and 1.5 µM) as eﬀectively as colchicine or vinblastine
(clinically-used microtubule targeting antimitotic drugs; GI50
1.4 µM, and 0.13 µM respectively);93 whereas 8 and 8a are less
potent (GI50 = 40.6 µM, 17 µM and 25.3 µM, respectively).
Furthermore, there is a correlation between the ability of
the complexes to inhibit the polymerisation of microtubules in
vitro and the quantity of Ru found in the cytoskeleton (Fig. 6).
Our data indicate that 7/8 might be able to interact with micro-
tubules in treated cells. This could lead to the observed G2/M
phase cell cycle arrest, ultimately inhibiting proliferation of
cells.
There is increasing interest in the activity of specific enan-
tiomers of chiral tubulin-targeting agents. For example,
natural colchicine has an aS,7S-absolute configuration, and is
much more potent than its enantiomer.94 These data indicate
the importance of the configuration of these agents.95 As
found for the tethered Ru complexes studied in this work. Our
results show that the chirality of the backbone or ruthenium
centre individually is not critical for inhibiting tubulin
polymerization. However, the combination of chiralities is
important for maintaining the potency of these tethered
ruthenium diastereoisomers. In addition, although 7 and 7a
show stronger inhibition of tubulin polymerisation than 8 and
8a, the trend is diﬀerent from that of the antiproliferation.
This suggests that other cellular targets, perhaps located in the
cytosol or membranes of cells, could have an important role in
the biological activity of such compounds.
Conclusions
Complexes 7/7a and 8/8a are Noyori-like ruthenium arene
transfer hydrogenation catalysts capable of the enantio-
selective reduction of ketones and imines through an ATH
mechanism following the trend 7 ≫ 8 in catalytic eﬃciency.
Our experiments show that their antiproliferative potency
towards cancer cells follows the trend 8, 8a >7 >7a. Complex 7
carrying the RR isomer of the TsDPEN derivative exhibits
higher activity than the SS derivative 7a. Unlike related
‘piano-stool’ ruthenium anticancer complexes,33,41,42 the
antiproliferative potency of these Noyori-like ruthenium cata-
lysts appears not to be related to their NADH catalytic activity
or to DNA binding. The antiproliferative activity (GI50 values)
of 7/7a and 8/8a appears to be related to their ability to
accumulate in cancer cells, and is at least partially linked to
their accumulation in the cytoskeleton, and inhibition of the
polymerisation of microtubules.
Methods
Materials
Complexes 7/8 were synthesised as previously described.75,92
The A2780 human ovarian carcinoma cell line was purchased
from European Collection of Animal Cell Cultures (ECACC),
Salisbury, UK), RPMI-1640, as well as, foetal bovine serum,
L-glutamine, penicillin/streptomycin mixture, trypsin, trypsin/
EDTA, phosphate buﬀered saline (PBS) were purchased from
GE Healthcare. Propidium iodide (>94%) and RNAse A were
obtained from Sigma Aldrich.
Cell culture
A2780 human ovarian carcinoma cells were used between pas-
sages 5 and 18 and grown in Roswell Park Memorial Institute
medium (RPMI-1640) supplemented with 10% of foetal calf
serum, 1% of 2 mM glutamine and 1% penicillin/strepto-
mycin. They were grown as adherent monolayers at 310 K in a
5% CO2 humidified atmosphere and passaged at approxi-
mately 70–80% confluence.
In vitro growth inhibition assays
The antiproliferative activity of complexes 7–8 was determined
in A2780 ovarian cancer cells. Briefly, 96-well plates were used
to seed 5000 cells per well. The plates were left to pre-incubate
with drug-free medium at 310 K for 48 h before adding
diﬀerent concentrations of the compounds to be tested. A drug
exposure period of 24 h was allowed. After this, supernatants
were removed by suction and each well was washed with PBS.
A further 48 h was allowed for the cells to recover in drug-free
medium at 310 K. The SRB assay was used to determine cell
viability. GI50 values, as the concentration which causes 50%
cell death, were determined as duplicates of triplicates in two
independent sets of experiments and their standard deviations
were calculated.
Cell viability modulation by co-administration of sodium
formate
Cell viability assays were carried out with complexes 7/8 in
A2780 ovarian cancer cells, as described above with the follow-
ing modifications: a fixed concentration of each Ru complex
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equal to 1/5 GI50 was used in co-administration with three
diﬀerent concentrations of sodium formate or sodium acetate
(0.5, 1.0 and 2.0 mM). To prepare the stock solution of the
drug, the complex was dissolved in 5% DMSO and, diluted in
a 1 : 1 mixture of 0.9% saline : cell culture medium. This stock
was further diluted using RPMI-1640 until working concen-
trations were achieved. Separately, stock solutions of sodium
formate were prepared in saline. The complex and formate
were added to each well independently, but within 5 min of
each other. The SRB assay was used to determine cell viability.
Cell proliferation was studied as duplicates of triplicates in two
independent sets of experiments and their standard deviations
were calculated.
NCI-60 cell screening
The protocols used in the National Cancer Institute (NCI)
screens have been described previously.96 Briefly, cells were
treated with complex for 48 h at five concentrations ranging
from 0.01 to 100 µM. Three endpoints were calculated: GI50
(the concentration to inhibit cell growth by 50%): TGI (the con-
centration to inhibit cell growth by 100%), LC50 (the concen-
tration which kills 50% of the original cell count), MG-MID
(full-panel mean-graph midpoint). The data reported for
cisplatin were from the most up-to-date NCI/DTP screening
conducted in March 2012.
Mean graphs and COMPARE analysis
Mean graphs were constructed by plotting positive and nega-
tive values along a vertical line, representing the mean
response over all cell lines in the panel (mean GI50). This is cal-
culated in 3 steps: (1) the GI50 value for each cell line tested
against each compound is converted to its corresponding log10
GI50 value; (2) log10GI50 values are averaged; (3) each log10 GI50
value is subtracted from the average to create a delta value.
These positive and negative deltas are plotted along a vertical
line which represents the mean response of all the 60 cell lines
in the NCI panel. Projections to the right indicate cell lines
with susceptibility that exceeds the mean, projections to the
left indicate cell lines with lower susceptibility. The COMPARE
analysis quantitatively compares the mean graph patterns of
compounds against the NCI/DTP Standard Agents Database
(a collection of 171 known anticancer compounds to provide
preliminary indications on a possible mechanism of action) and
the Synthetic Agents Database (>40 000 pure natural and syn-
thetic compounds).97 For this analysis, we assessed the top 10
returned hits in each database, for positive and negative corre-
lations. High positive Pearson correlations (r ≥ 0.6) to agents in
each database may indicate similar anti-cancer mechanism.
Interactions with nucleobases
The reaction of complex 8a (1.5 mM) with the nucleobases
9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA) typically
involved addition of a solution containing 1 mol equiv. of
nucleobase in D2O to an equilibrium solution of complex 8a
in 25% MeOD-d4/75% D2O (v/v).
1H NMR spectra of these
solutions were recorded at 310 K after 10 min and 24 h.
Interactions with NADH
The reaction of complex 8a (1.5 mM) with NADH typically
involved addition of a solution containing 3 mol equiv. of
NADH in H2O to an equilibrium solution of complex 8a
in 25% MeOD-d4/75% H2O (v/v).
1H NMR spectra of these
solutions were recorded at 298 K after 10 min and 3 h.
Ruthenium accumulation in whole cancer cells
Cell accumulation studies for metal complexes 7 and 8 were
conducted on A2780 ovarian cells. Briefly, 10 × 106 cells were
seeded on 145 mm petri dishes. After 24 h of pre-incubation
time in drug-free medium at 310 K, the complexes were added
to give final concentrations equal to GI50 or 2 µM and a further
24 h of drug exposure was allowed. After this time, cells were
treated with trypsin, counted, and cell pellets were collected.
Each pellet was digested overnight in concentrated nitric acid
(73%) at 353 K; the resulting solutions were diluted with
double-distilled water to a final concentration of 5% HNO3
and the amount of Ru taken up by the cells was determined by
ICP-MS (Agilent technologies 7500 series). Data acquisition
was carried out in ICP-MS top B.03.05 and analysis on oﬄine
Data analysis B.03.05). These experiments did not include any
cell recovery time in drug-free media; they were carried out in
triplicate and the standard deviations were calculated.
Ruthenium distribution in cancer cells
Cell pellets were obtained as described above, and were fractio-
nated using the Fraction PREP kit from BioVision according to
the supplier’s instructions. Each sample was digested overnight
in concentrated nitric acid (73%) and the amount of Ru taken
up by the cells was determined by ICP-MS. Data acquisition was
carried out in ICP-MS top B.03.05 and analysis on oﬄine Data
analysis B.03.05). These experiments were all carried out in
triplicate and the standard deviations were calculated.
Cell cycle analysis
A2780 ovarian cancer cells were seeded in a 6-well plate using
1.0 × 106 cells per well. They were pre-incubated in drug-free
media at 310 K for 24 h, after which complexes were added at
concentrations equal to 2 µM (or 100 nM for Colchicine and
Taxol controls). After 24 h of drug exposure, supernatants were
removed by suction and cells were washed with PBS. Finally,
cells were harvested using trypsin. DNA staining was achieved
after cold ethanol fixation by re-suspending the cell pellets in
PBS containing propidium iodide (PI) and RNAse A. Cell pellets
were re-suspended in PBS before being analysed by flow cyto-
metry using the maximum excitation of PI-bound DNA at
536 nm, and its emission at 617 nm. Data were processed using
Flowjo software. These experiments were carried out in tripli-
cate, although only selected histograms are shown, full numeri-
cal data and statistical analysis can be found in the ESI.†
Microtubule polymerisation assays
The eﬀect of complexes 7 and 8 on tubulin polymerisation was
determined using a fluorescence-based tubulin polymerisation
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assay (BK011P; Cytoskeleton, Inc.) according to the supplier’s
instructions. Measurements were performed in a plate reader
GloMax®-Multi+ Detection System with Temperature Control
(E9032; Promega) equipped with a fluorescence module
(E8051; Promega) using the UV fluorescence optical kit (λexc
365 nm; λem 410–460 nm). IC50 values, as the concentration
which causes 50% polymerisation inhibition, were determined
as duplicates.
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